-
Something wrong with this record ?
Secretion and surface display of binders of IL-23/IL-17 cytokines and their receptors in Lactococcus lactis as a therapeutic approach against inflammation
TV. Plavec, K. Klemenčič, M. Kuchař, P. Malý, A. Berlec
Language English Country Netherlands
Document type Journal Article
- MeSH
- Albumins metabolism MeSH
- Cytokines * metabolism MeSH
- Immunologic Factors MeSH
- Interleukin-17 metabolism MeSH
- Interleukin-23 chemistry metabolism MeSH
- Lactococcus lactis * genetics metabolism MeSH
- Humans MeSH
- Antibodies, Monoclonal MeSH
- Recombinant Proteins metabolism MeSH
- Carrier Proteins metabolism MeSH
- Inflammation MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
The cytokine IL-23 activates the IL-23 receptor (IL-23R) and stimulates the differentiation of naïve T helper (Th) cells into a Th17 cell population that secretes inflammatory cytokines and chemokines. This IL-23/Th17 proinflammatory axis drives inflammation in Crohn's disease and ulcerative colitis and represents a therapeutic target of monoclonal antibodies. Non-immunoglobulin binding proteins based on the Streptococcus albumin-binding domain (ABD) provide a small protein alternative to monoclonal antibodies. They can be readily expressed in bacteria. Lactococcus lactis is a safe lactic acid bacterium that has previously been engineered as a vector for the delivery of recombinant therapeutic proteins to mucosal surfaces. Here, L. lactis was engineered to display or secrete ABD-variants against the IL-17 receptor (IL-17R). Its expression and functionality were confirmed with flow cytometry using specific antibody and recombinant IL-17R, respectively. In addition, L. lactis were engineered into multifunctional bacteria that simultaneously express two binders from pNBBX plasmid. First, binders of IL-17R were combined with binder of IL-17. Second, binders of IL-23R were combined with binders of IL-23. The dual functionality of the bacteria was confirmed by flow cytometry using corresponding targets, namely the recombinant receptors IL-17R and IL-23R or the p19 subunit of IL-23. Binding of IL-17 was confirmed by ELISA. With the latter, 97% of IL-17 was removed from solution by 2 × 109 recombinant bacteria. Moreover, multifunctional bacteria targeting IL-17/IL-17R prevented IL-17A-mediated activation of downstream signaling pathways in HEK-Blue IL-17 cell model. Thus, we have developed several multifunctional L. lactis capable of targeting multiple factors of the IL-23/Th17 proinflammatory axis. This represents a novel therapeutic strategy with synergistic potential for the treatment of intestinal inflammations.
Department of Biotechnology Jožef Stefan Institute Jamova 39 Ljubljana SI 1000 Slovenia
Faculty of Pharmacy University of Ljubljana Aškerčeva 7 Ljubljana SI 1000 Slovenia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000879
- 003
- CZ-PrNML
- 005
- 20240213093434.0
- 007
- ta
- 008
- 240109e20230822ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejps.2023.106568 $2 doi
- 035 __
- $a (PubMed)37619953
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Plavec, Tina Vida $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, Ljubljana SI-1000, Slovenia; Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, Ljubljana SI-1000, Slovenia
- 245 10
- $a Secretion and surface display of binders of IL-23/IL-17 cytokines and their receptors in Lactococcus lactis as a therapeutic approach against inflammation / $c TV. Plavec, K. Klemenčič, M. Kuchař, P. Malý, A. Berlec
- 520 9_
- $a The cytokine IL-23 activates the IL-23 receptor (IL-23R) and stimulates the differentiation of naïve T helper (Th) cells into a Th17 cell population that secretes inflammatory cytokines and chemokines. This IL-23/Th17 proinflammatory axis drives inflammation in Crohn's disease and ulcerative colitis and represents a therapeutic target of monoclonal antibodies. Non-immunoglobulin binding proteins based on the Streptococcus albumin-binding domain (ABD) provide a small protein alternative to monoclonal antibodies. They can be readily expressed in bacteria. Lactococcus lactis is a safe lactic acid bacterium that has previously been engineered as a vector for the delivery of recombinant therapeutic proteins to mucosal surfaces. Here, L. lactis was engineered to display or secrete ABD-variants against the IL-17 receptor (IL-17R). Its expression and functionality were confirmed with flow cytometry using specific antibody and recombinant IL-17R, respectively. In addition, L. lactis were engineered into multifunctional bacteria that simultaneously express two binders from pNBBX plasmid. First, binders of IL-17R were combined with binder of IL-17. Second, binders of IL-23R were combined with binders of IL-23. The dual functionality of the bacteria was confirmed by flow cytometry using corresponding targets, namely the recombinant receptors IL-17R and IL-23R or the p19 subunit of IL-23. Binding of IL-17 was confirmed by ELISA. With the latter, 97% of IL-17 was removed from solution by 2 × 109 recombinant bacteria. Moreover, multifunctional bacteria targeting IL-17/IL-17R prevented IL-17A-mediated activation of downstream signaling pathways in HEK-Blue IL-17 cell model. Thus, we have developed several multifunctional L. lactis capable of targeting multiple factors of the IL-23/Th17 proinflammatory axis. This represents a novel therapeutic strategy with synergistic potential for the treatment of intestinal inflammations.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a cytokiny $x metabolismus $7 D016207
- 650 _2
- $a interleukin-17 $x metabolismus $7 D020381
- 650 12
- $a Lactococcus lactis $x genetika $x metabolismus $7 D013294
- 650 _2
- $a imunologické faktory $7 D007155
- 650 _2
- $a zánět $7 D007249
- 650 _2
- $a transportní proteiny $x metabolismus $7 D002352
- 650 _2
- $a rekombinantní proteiny $x metabolismus $7 D011994
- 650 _2
- $a albuminy $x metabolismus $7 D000418
- 650 _2
- $a interleukin-23 $x chemie $x metabolismus $7 D053759
- 650 _2
- $a monoklonální protilátky $7 D000911
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Klemenčič, Kaja $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, Ljubljana SI-1000, Slovenia
- 700 1_
- $a Kuchař, Milan $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, v. v. i., Průmyslová 595, Vestec 252 50, Czech Republic
- 700 1_
- $a Malý, Petr $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, v. v. i., Průmyslová 595, Vestec 252 50, Czech Republic
- 700 1_
- $a Berlec, Aleš $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, Ljubljana SI-1000, Slovenia; Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, Ljubljana SI-1000, Slovenia. Electronic address: ales.berlec@ijs.si
- 773 0_
- $w MED00001639 $t European journal of pharmaceutical sciences $x 1879-0720 $g Roč. 190 (20230822), s. 106568
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37619953 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093431 $b ABA008
- 999 __
- $a ok $b bmc $g 2049473 $s 1210573
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 190 $c - $d 106568 $e 20230822 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur. j. pharm. sci. (Print) $x MED00001639
- LZP __
- $a Pubmed-20240109